The Business Times
business-time-50
SUBSCRIBERS

AstraZeneca spins off autoimmune drugs into new biotech company

google-preferred-sourceAdd BT as a preferred source
Published Wed, Feb 28, 2018 · 09:50 PM

DeeperDive is a beta AI feature. Refer to full articles for the facts.

London

ASTRAZENECA is spinning off six early-stage experimental drugs into a new US$250 million stand-alone biotech company focused on severe autoimmune diseases.

The spin-off of the three clinical and three pre-clinical biological compounds, announced on Wednesday, is the latest example of the British drugmaker pruning its non-core drug development work to focus on priority areas, notably in cancer.

AstraZeneca

Share with us your feedback on BT's products and services

Feedback

TRENDING NOW

DBS filed the bankruptcy application after serving statutory demands to the directors of Autobahn Rent A Car in December 2025.

Autobahn Rent A Car directors declared bankrupt over S$50 million each owed to DBS

Loyang Valley sits on a 840,648 sq ft plot of land, which now houses 362 apartments.

Loyang Valley sold for S$880 million to SingHaiyi-led consortium

The price tag for the Nassim Road GCB works out to nearly S$4,550 per square foot.

Nassim Road bungalow changing hands for S$64.9m 

Property-based taxes may have limited room to run – and pushing them further risks hitting the wrong people, observers say.

In taxing wealth, how far can Singapore push property owners?

Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
View More